Protagonist Therapeutics Inc (PTGX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Protagonist Therapeutics Inc (PTGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9836
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. The company’s product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and disorders. It operates in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.

Protagonist Therapeutics Inc (PTGX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Protagonist Therapeutics Raises USD40 Million in Series C Financing 11
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 13
Partnerships 14
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
Licensing Agreements 15
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 15
Equity Offering 17
Protagonist Therapeutics to Raise USD22 Million in Private Placement of Shares 17
Protagonist Therapeutics Prices Public Offering of Shares for USD60 Million 18
Protagonist Therapeutics Raises USD90 Million in IPO 19
Protagonist Therapeutics Inc – Key Competitors 21
Protagonist Therapeutics Inc – Key Employees 22
Protagonist Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Protagonist Therapeutics reports second quarter 2018 financial results 24
May 09, 2018: Protagonist Therapeutics Reports First Quarter 2018 Financial Results 26
Mar 07, 2018: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results 28
Nov 06, 2017: Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 30
Aug 08, 2017: Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights 32
May 10, 2017: Protagonist Therapeutics Reports First Quarter 2017 Financial Results 34
Mar 07, 2017: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 35
Corporate Communications 36
May 24, 2018: Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer 36
May 16, 2018: Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors 37
Dec 14, 2017: Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors 38
Jun 08, 2017: Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. “Rusty” Williams, to its Board of Directors 39
Product News 40
09/06/2018: Protagonist Therapeutics receives $1.45 million SBIR funding for the development of PTG-300 40
Product Approvals 41
Mar 06, 2018: FDA Grants Orphan Drug Designation for Protagonist Therapeutics’ PTG-300 for the Treatment of Beta-Thalassemia 41
Clinical Trials 42
Sep 27, 2018: Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 42
Jun 18, 2018: Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting 43
May 17, 2018: Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association 44
Dec 14, 2017: Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 45
Sep 20, 2017: Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 46
May 25, 2017: Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protagonist Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Protagonist Therapeutics Raises USD40 Million in Series C Financing 11
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 15
Protagonist Therapeutics to Raise USD22 Million in Private Placement of Shares 17
Protagonist Therapeutics Prices Public Offering of Shares for USD60 Million 18
Protagonist Therapeutics Raises USD90 Million in IPO 19
Protagonist Therapeutics Inc, Key Competitors 21
Protagonist Therapeutics Inc, Key Employees 22
Protagonist Therapeutics Inc, Subsidiaries 23

List of Figures
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Protagonist Therapeutics Inc (PTGX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Merit Medical Systems Inc (MMSI):医療機器:M&Aディール及び事業提携情報
    Summary Merit Medical Systems, Inc. (Merit Medical) offers a wide range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolyti …
  • Avista Corporation (AVA):電力:M&Aディール及び事業提携情報
    Summary Avista Corporation (Avista) is an electric and natural gas utility. The company produces, transmits, and distributes electricity; and supplies natural gas on retail and wholesale basis. It sources electricity from its facilities and contracted hydroelectric, thermal and wind generation facil …
  • Crew Energy Inc (CR):企業の財務・戦略的SWOT分析
    Summary Crew Energy Inc (Crew Energy) is an exploration and production company that offers our long-term production and development of crude oil and natural gas resources. The company offers exploration, development, strategic acquisitions, operations, management, and production programs. It operate …
  • The Williams Companies Inc (WMB):企業の財務・戦略的SWOT分析
    The Williams Companies Inc (WMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • EnBW Energie Baden-Wuerttenberg AG:戦略・SWOT・企業財務分析
    EnBW Energie Baden-Wuerttenberg AG - Strategy, SWOT and Corporate Finance Report Summary EnBW Energie Baden-Wuerttenberg AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • SciBase AB (SCIB):企業の財務・戦略的SWOT分析
    Summary SciBase AB (SciBase) is a medical technology company, which offers non-invasive detection and monitoring of skin tissue alterations. The company develops point of care device for the accurate detection of malignant melanoma. It offers electrical impedance spectroscopy which uses the varying …
  • eHealthInsurance Services Inc:企業の戦略的SWOT分析
    eHealthInsurance Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Bridgeport Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Bridgeport Energy Ltd (Bridgeport Energy), a subsidiary of New Hope Corporation Limited is an oil and gas company that explores, produces and develops oil and gas. The company acquires and operates oil and gas assets in Australia and internationally. It holds and operates assets located in t …
  • McPherson’s Ltd (MCP):企業の財務・戦略的SWOT分析
    McPherson's Ltd (MCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cymbet Corp:電力:M&Aディール及び事業提携情報
    Summary Cymbet Corp (Cymbet) is a clean technology company that offers energy storage solutions for microelectronic systems. The company’s products include EnerChip, EnerChip solid state batteries, EnerChip bare die, EnerChip RTC and evaluation kits. Its devices offers new concept in energy storage …
  • Laboratoires Thea SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratoires Thea SA (Thea) is an independent pharmaceutical company that researches, develops, manufactures, and commercializes a range of eye care products. The company’s products find application in the diagnosis, surgery and treatment of ophthalmic diseases such as dry eye, allergies, gl …
  • Aerosonic, LLC:企業の戦略・SWOT・財務情報
    Aerosonic, LLC - Strategy, SWOT and Corporate Finance Report Summary Aerosonic, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Spark New Zealand Ltd:企業の戦略・SWOT・財務情報
    Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report Summary Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Maxeda B.V.:戦略・SWOT・企業財務分析
    Maxeda B.V. - Strategy, SWOT and Corporate Finance Report Summary Maxeda B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Schott AG:企業の戦略的SWOT分析
    Schott AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • PerkinElmer Inc (PKI):企業の財務・戦略的SWOT分析
    PerkinElmer Inc (PKI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PT Supreme Cable Manufacturing & Commerce Tbk (SCCO):企業の財務・戦略的SWOT分析
    PT Supreme Cable Manufacturing & Commerce Tbk (SCCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Jun Yang Financial Holdings Ltd:企業のM&A・事業提携・投資動向
    Jun Yang Financial Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jun Yang Financial Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Montefiore Medical Center-医療機器分野:企業M&A・提携分析
    Summary Montefiore Medical Center (MMC) is a healthcare service provider that offers clinical services. The center offers services such as allergy and immunology, orthopaedics, dentistry and oral surgery, dermatology, endocrinology, digestive and liver diseases, neurological surgery, otorhinolaryngo …
  • Vycor Medical Inc (VYCO):企業の財務・戦略的SWOT分析
    Summary Vycor Medical Inc (Vycor) is a medical device company that develops, designs, and markets medical devices for use in neurosurgery. The company offers computer-based light stimulation therapies for patients suffering from vision loss resulting from neurological trauma such as stroke. It provi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆